Citations

Citations to this article as recorded by  

• Seizure recurrence after GLP‐1 receptor agonist initiation in adults with epilepsy
  Majd A. AbuAlrob, Abdullah Hussein, Rand Abdellatif, Adham Itbaisha, Khaled Zammar, Boulenouar Mesraoua
  Epilepsia.2026; 67(3): 1246.     CrossRef
• Engineered exosomal delivery of semaglutide activates SIRT1–FOXO3a–miR-124 signaling and protects against cortical neuroinflammation
  Elsayed A. Elmorsy, Sameh Saber, Ahmed Y. Kira, Manal Mohamed Hatem, Mohammed Alorini, Suzan Awad AbdelGhany Morsy, Hamad Alsaykhan, Abdulaziz A. Alsalloom, Nahla B. Mohamed, Norah Suliman Alsoqih, Rabab S. Hamad, Youssef El-Sayed, Nagwa Mahmoud Ramadan,
  Journal of Drug Delivery Science and Technology.2026; 118: 108078.     CrossRef
• Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations
  Nimet Yılmaz, Mehmet Bastemir
  Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists and Acute Pancreatitis: Current Evidence and Clinical Implications
  Kwang Hyun Chung, Jaihwan Kim
  The Korean Journal of Pancreas and Biliary Tract.2026; 31(1): 1.     CrossRef
• Single vs. Dual Agonist Pharmacotherapy for Managing Insufficient Weight Loss and Weight Regain Following Metabolic and Bariatric Surgery: A Comparative Review
  Claudia Reytor-González, Martín Campuzano-Donoso, Gerardo Sarno, Martha Montalvan, Raquel Horowitz, Gianluca Rossetti, Vincenzo Pilone, Luigi Barrea, Giovanna Muscogiuri, Luigi Schiavo, Daniel Simancas-Racines
  Nutrients.2026; 18(4): 553.     CrossRef
• Oral Administration of Crocus sativus Tepals Extract Restores High‐Fat Diet‐Induced Gut Dysbiosis and Modulates Intestinal Inflammation and Hepatic Lipid Metabolism
  Biljana Bursać, Miloš Vratarić, Ljupka Gligorovska, Luisa Bellachioma, Ana Teofilović, Danijela Vojnović Milutinović, Camilla Morresi, Elisabetta Damiani, Tiziana Bacchetti, Ana Djordjevic
  BioFactors.2026;[Epub]     CrossRef
• A Rare Case of Semaglutide-Associated Small Bowel Obstruction Complicated by Acute Kidney Injury Requiring Dialysis
  Suhasini Rallabandi, Mansi Sharma, Krishnamraju Kosuru, Rahul Kashyap
  Cureus.2026;[Epub]     CrossRef
• The pancreatic signal of GLP‐1 receptor agonists: A biliary phenomenon rather than direct toxicity
  Andro Koren, Luciana Koren
  British Journal of Clinical Pharmacology.2026;[Epub]     CrossRef
• Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea
  Anish Preshy, Cornelius J. Fernandez, Mohammad Hamid Nedai, Joseph M. Pappachan
  Chronic Diseases and Translational Medicine.2026; 12(2): 100.     CrossRef
• Practical management of glucagon-like peptide-1 receptor agonists in gastroenterology: a position paper by the Italian Society of Gastroenterology (SIGE)
  Antonio Facciorusso, Edoardo G Giannini, Matteo Tacelli, Alberto Zanetto, Cristiano Spada, Ivo Boskoski, Manuele Furnari, Grazia Pennisi, Gabriele Capurso, Alessandro Vitello, Giovanni Marasco, Giovanni Sarnelli, Luca Frulloni, Marcello Maida
  Digestive and Liver Disease.2026; 58(6): 737.     CrossRef
• Adverse effects of GLP-1 receptor agonists: Clinical Implications, regulatory perspectives, and future directions
  Riad Mohammed Abdelrahman, Taha Hussein Musa, Ismail Adam Arbab, Eltieb Omer Ahmed, Sahar Ibrahim Gasmallah, Mohammed Jalal, Chiamaka Linda Mgbechidinma, Wafaa Ramadan Ahmed
  Obesity Medicine.2026; 61: 100699.     CrossRef
• New generation anti-obesity drugs and bone health in postmenopausal women
  Jana Tomasová Studýnková
  Vnitřní lékařství.2026; 72(2): 104.     CrossRef
• Re-establishing alliances: “Old Friends” confronting obesity, inflammation, and stress-related psychiatric disorders
  Luke W. Desmond, Christopher A. Lowry
  Brain Behavior and Immunity Integrative.2026; 15: 100166.     CrossRef
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Limosilactobacillus fermentum K8-Lb1 Postbiotic on Weight Management and Metabolic Health Outcomes
  Ekaterina Papazova, Susanne Mitschke, Christiane Laue, Jürgen Schrezenmeir
  Nutrients.2026; 18(8): 1174.     CrossRef
• Appetite Regulation and Gastric Emptying of Semaglutide in Non-Diabetic Obese Adults: A Systematic Review
  Uchechukwu Bethel Abioke, Isaac Baiden, Obiageri Ihuarulam Okeoma, Victoria Partey-Newman, Temitope Oluwatosin Adewale, Shadrach Oluchi Onyekezini, Ijeoma Linda Okwuowulu
  Epidemiology and Health Data Insights.2026; 2(3): ehdi035.     CrossRef
• Assessment of knowledge, attitude, and practices towards the usage of antidiabetic drugs for weight loss among Lebanese population
  Dima Kreidieh, Rouba Ballout, Rana Abutaima, Samer A. Kharroubi, Fatima A. Saleh
  BMC Public Health.2026;[Epub]     CrossRef
• A Narrative Review of Weight Management Strategies: From Lifestyle Interventions to Emerging Pharmacotherapies
  Iman Saad Ahmed, Sara Luay Tapponi, Hala Malek Manaa, Amina Soltani, Elzahraa Shehata Hussein, Fatemeh Ali Parvaresh, Zahid Hussain, Jasbir Arora (RSS)
  Journal of Obesity.2026;[Epub]     CrossRef
• The case for primary prevention of obesity in the era of GLP-1 therapies
  Søren Holm, Manuel Tena-Sempere, Dimitrios Koutsouris, George V. Dedoussis, Karl-Heinz Wagner, Sara Arranz, Philippe Froguel, Torsten Bohn, Paulo J. Oliveira, Jeroen Lakerveld, Aakruti Kaikini, Achim Kramer, Adam Selamnia, Adina Weinberger, Adrian Jauch,
  The Lancet Regional Health - Europe.2026; 66: 101679.     CrossRef
• The neuro-metabolic epidemic and the CB1R paradox
  Francesca Vaccaro, Ginevra Malta, Manfredi Rizzo, Fulvio Plescia, Gianluca Lavanco
  Current Opinion in Pharmacology.2026; 89: 102631.     CrossRef
• Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis
  Riad Mohammed Abdelrahman, Taha Hussein Musa, Ismail Adam Arbab, Eltieb Omer Ahmed, Sahar Ibrahim Gasmallah, Mohammed Jalal, Wafaa Ramadan Ahmed, Khalid Hamid Fadul
  INQUIRY: The Journal of Health Care Organization, Provision, and Financing.2026;[Epub]     CrossRef
• GIPR:GCGR co-agonism restores normal weight in obese rodents
  Diego Perez-Tilve, Fa Zhang, Yujin Zhang, Kaitlyn Lohman, Joyce Sorrell, Andrew Vick, Timo D. Müller, Matthias H. Tschöp, Richard D. DiMarchi
  Molecular Metabolism.2026; 108: 102365.     CrossRef
• Comparative effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists on the risk of incident dementia after acute kidney injury: a target-trial emulation
  Ying-Ru Chen, Zheng-Hong Jiang, Jui-Yi Chen, Vin-Cent Wu
  GeroScience.2026;[Epub]     CrossRef
• The Gastrointestinal Safety of Orforglipron, a GLP‐1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta‐Analysis of Randomized Controlled Trials
  Ahmed W. Hageen, Ahmed Farid Gadelmawla, Ahmad Omar Saleh, Abdallfatah Abdallfatah, Mohamed Reyad Mohamed, Amira Fahmy El‐Nemr, Odai Maihoub, Ahmed Elsekhary, Safir Eladawi, Biruk Demisse Ayalew, Ahmed Mansour, Ayoup Ahmed Radi, Mohamed Abuelazm, Mohamed
  Endocrinology, Diabetes & Metabolism.2026;[Epub]     CrossRef
• Tirzepatide versus Semaglutide: Selecting the Right Agent for the Right Patient in Contemporary Metabolic Care
  Ahmad Alam
  Bangladesh Journal of Endocrinology and Metabolism.2026;[Epub]     CrossRef
• Systematic Characterisation of GLP‐1R in Human Enteric Nervous System: Implications for GLP‐1 as a Key Regulator of Colonic Activity
  Kiran Devi Dontamsetti, Rubina Aktar, Madusha Peiris
  Journal of Neurochemistry.2026;[Epub]     CrossRef
• Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis
  Po-Lung Cheng, Hua-Ching Chang
  Diabetes Research and Clinical Practice.2026; 237: 113333.     CrossRef
• Unexpected Therapeutic Effect of GLP-1 Receptor Agonists in Patients With Refractory IBS-D: A Case Series
  Solangel Isabelle Suarez, Bilori Bilori, Sai Venkat Aluri, Saurav Das
  Annals of Internal Medicine: Clinical Cases.2026;[Epub]     CrossRef
• Cardiometabolic 2.0: Redefining Cardiovascular Prevention Through SGLT-2 Inhibitors and GLP-1 Receptor Agonists
  Maria-Daniela Tanasescu, Andrei-Mihnea Rosu, Alexandru Minca, Maria-Mihaela Grigorie, Delia Timofte, Dorin Ionescu
  Life.2026; 16(5): 756.     CrossRef
• Microneedles (MNs)-based technology for diabetes management: design, delivery, and artificial intelligence integration
  Fuad Saleh, Zakarya A.M. Hazaea, Mansour Alantry Abdu, Waleed Alahmad, Mohammad Ashfaq
  Inorganic Chemistry Communications.2026; 190: 116931.     CrossRef
• Nutritional Care for Adults With Obesity Treated With Glucagon-Like Peptide (GLP)-1 and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists: A Review of Evidence, Gaps, and Clinical Implications
  Cici McGuane, Nosha Farhadhar, Khavir A Sharieff, Stephanie N Petrosky, Karima Alabasi
  Cureus.2026;[Epub]     CrossRef
• New Avenues in Adjunctive Pharmacotherapy for Substance Use Disorders
  David Crockford, Anees Bahji
  Canadian Journal of Addiction.2026; 17(2): 4.     CrossRef
• Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance
  Raynier Zambrano-Villacres, Martín Campuzano-Donoso, Claudia Reytor-González, Gianluca Rossetti, Luigi Cobellis, Francesco Cobellis, Vincenzo Pilone, Daniel Simancas-Racines, Luigi Schiavo
  Nutrients.2026; 18(11): 1751.     CrossRef
• Obesity Management in Primary Care: Clinical Approaches and Policy Implications in the Era of Incretin-Based Therapies
  Chung-woo Lee
  Korean Journal of Family Practice.2026; 16(2): 81.     CrossRef
• GLP‐1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study
  Jisu Park, Ju Hwan Kim, Yoon Seob Kim, Gyeongmin Lim, Hong Ji Song, Sang Youl Rhee, Seonghoon Hwang, Daeun Cho, Minyoung Kim, Bo‐Yeon Kim, Chang Won Jeong, Dae‐Yeon Kim, Hang A Park, Min‐Ho Kim, Seong Hwan Kim, Won‐Woo Seo, Woo Jin Kim, Young Sung Suh, Ra
  Diabetes, Obesity and Metabolism.2026; 28(9): 8649.     CrossRef
• Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study
  Chungsoo Kim, Seonji Kim, Dong Yun Lee, Eugene Han, Yong‐ho Lee, Seng Chan You
  Diabetes, Obesity and Metabolism.2026; 28(9): 8482.     CrossRef
• Avoiding Malnutrition in the Era of Glucagon-Like Peptide-1 Medications: Emerging Evidence and Opportunities for Integrated Nutrition Care
  Paola Mogna-Peláez, Marta Guasch-Ferré
  The Journal of Nutrition.2026; 156(8): 101684.     CrossRef
• Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation
  Shashank R. Joshi, Anoop Misra, Ambrish Mithal, Banshi Saboo, Krishna G. Seshadri, Subhankar Chowdhury, Ganapathi Bantwal, Bipin Sethi, Jothydev Kesavadev, Arpan Dev Bhattacharya, Manash P. Baruah, Ajay Budhwar, Priti Thakor, Sachin Shende, Viswanathan Mo
  Obesity Pillars.2026; 19: 100296.     CrossRef
• Mapping the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Aesthetic and Reconstructive Plastic Surgery: A Bibliometric Analysis of the 50 Most Cited Studies
  Edoardo Caimi, Emanuele Mark Ghetti, Federico Giovagnoli, Stefano Vaccari, Gianmaria Ceglia, Mattia Federico Cavallero, Roberta Comunian, Riccardo Di Giuli, Alessandra Veronesi, Francesco Klinger, Valeriano Vinci
  Aesthetic Plastic Surgery.2026; 50(17): 7549.     CrossRef
• Glucagon-like Peptide-1 Receptor Agonists and Chronic Pain: Preclinical Antinociceptive Mechanisms, Indirect Metabolic–Functional Effects, and Clinical Considerations—A Narrative Review
  Sung-woo Hyung, Ui Jin Park, Jeong Hwan Ryu, Siwook Chung
  Journal of Clinical Medicine.2026; 15(15): 5932.     CrossRef
• Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review
  Wah-Kheong Chan, Hak-Keith Leung, Guo-Jeng Tan, Quan-Hziung Lim, Lee-Ling Lim, Jeyakantha Ratnasingam, Shireene Ratna Vethakkan
  Journal of Obesity & Metabolic Syndrome.2026; 35(3): 298.     CrossRef
• Perceptions, attitudes, and experiences of GLP-1 receptor agonists for weight management in the United Kingdom: a cross-sectional survey study
  Jason Tallis, Darren Richardson, Michael J Duncan, Ricardo Martins, Thomas M Barber, Leigh Breen, Anna Higo, Helen M Jones, David R Broom
  BMC Public Health.2026;[Epub]     CrossRef
• Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes
  Artur Dziewierz, Natalia Kulicka, Krzysztof Łupina, Natalia Maruszak, Aleksandra Gałuszka, Justyna Domienik-Karłowicz, Anna Rulkiewicz, Zbigniew Siudak
  Diabetes Research and Clinical Practice.2026; 239: 113493.     CrossRef
• Glucagon‐Like Peptide‐1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure
  Cali Loblundo, Sammy Y. Gao, Shaun A. Nguyen, Mohamed Abdelwahab
  Otolaryngology–Head and Neck Surgery.2026;[Epub]     CrossRef
• Glucose-responsive probiotics for glycaemic modulation in mice and monkeys
  Ningzi Guan, Deqiang Kong, Xianyun Gao, Lingxue Niu, Yang Zhou, Guiling Yu, Tian Gao, Mengyao Liu, Wenbo Ma, Yiyu Jin, Jianli Yin, Shangang Zhao, Haifeng Ye
  Nature.2026; 657(8131): 477.     CrossRef
• GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals
  Alessandro Conforti, Carlos Cifuentes-González, Kajal Rupesh Agrawal, Rupesh Agrawal
  Drug Discovery Today.2026; 31(5): 104786.     CrossRef
• DIFFERENCES IN SAFETY PROFILE AND ADVERSE EFFECTS OF ORAL AND SUBCUTANEOUS GLP-1 ANALOGUES: A SYSTEMATIC REVIEW AND REAL-WORLD DATA ANALYSIS (2024–2026)
  Aleksandra Olga Pakulska, Natalia Rządzińska, Aleksandra Maria Błoch, Kornelia Julia Fimiarz, Aleksandra Katarzyna Kłosowicz, Maria Anna Miller, Aleksandra Jolanta Kamińska
  International Journal of Innovative Technologies in Social Science.2026;[Epub]     CrossRef
• Prospects for the use of new antidiabetic drugs in rheumatology
  E. L. Nasonov, M. V. Shestakova, L. V. Kondratyeva, M. S. Eliseev
  Rheumatology Science and Practice.2026; 64(4): 315.     CrossRef
• Microbiome and Metabolomics in Obesity: Advances in Understanding and Interventions Across the Lifespan
  Ioanna Panagiota Kalafati, David Krongauz, Alice Bosco, Antonio Noto, Cristina Piras, Maria Kafyra, Angelica Dessì, Matteo Mauri, Luigi Atzori, Adina Weinberger, Vassilios Fanos, George V. Dedoussis
  Obesity Reviews.2026;[Epub]     CrossRef
• Shifting the Paradigm in Global Diabetes Management: Beyond Glycohemoglobinism and Toward Etiological Mitigation via Minimizing Insulin Resistance on the Basis of Pharmacogenetics
  Sidhartha D. Ray, Lining Liang He, Stratton Rottersmann, Christina Hand, Maria Di Leo, Alec Chunilall, Ian G. Gray, Ngo Tsun Siu, Sonia Jong, Nigel Sirois, Kaitlin M. McNeely, Margarett A. Costes
  Diabetology.2026; 7(9): 176.     CrossRef
• Glucagon-like peptide-1 receptor agonists in dermatology: ethical considerations
  Chelsea Deitelzweig, Fatima Rahim, Benjamin K Stoff
  Clinics in Dermatology.2026;[Epub]     CrossRef
• Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies
  Ji Yoon Kim, Nam Hoon Kim
  Diabetes & Metabolism Journal.2026; 50(5): 844.     CrossRef
• Incretin-based obesity management medications: Implications for clinical practice and future perspectives
  Sanja Klobučar, Andrej Belančić, Elvira Meni Maria Gkrinia, Tomislav Božek, Ida Štimac, Andreea Ciudin Mihai
  Best Practice & Research Clinical Gastroenterology.2026; : 102141.     CrossRef
• Type 2 diabetes mellitus: emerging mechanistic insights, evolving therapeutic strategies, and future perspectives
  Himanshu, Suryakant Verma, Sonam Yadav, Asmita Singh, Jaishiv Chauhan, Sameeksha, Kshitiz Sahu, Anup Kumar Mamgain
  Discover Endocrinology and Metabolism.2026;[Epub]     CrossRef
• Severe Thrombocytopenia Associated With Glucagon‐Like‐1 Receptor Agonists (GPL‐1RA): A SONAR Report
  Charles L. Bennett, Chadi Nabhan, Demir Uslu, Yogitha Dadi, David Aboulafia, Barbara Senger, Joseph Magagnoli, Kelvin Rojas, Gurdeep Singh, Linda Martin, Edward Smith, Samuel Ruder, Chien‐Hsiang Weng, Nikhil Uppal, Mia Lynch, James B. Bussel
  Diabetes, Obesity and Metabolism.2026;[Epub]     CrossRef
• Long-term GLP-1 receptor agonist therapy in obesity: expert panel recommendations for good clinical practice
  Davide Brancato, Giorgio Borretta, Marco Chianelli, Olga Disoteo, Marco Grasso, Franco Grimaldi, Edoardo Guastamacchia, Fabrizio Muratori, Salvatore Oleandri, Marcello Orio, Paola Pantanetti, Enrico Papini, Agnese Persichetti, Roberto Vettor, Federica Vin
  Frontiers in Endocrinology.2026;[Epub]     CrossRef
• Impact of Glucagon-Like Peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP) Receptor Agonists on Intraocular Pressure in Glaucoma: A Case Series
  Coy Steel, Catherine Johnson, Chase Paulson, Jesse Terrell, Qi N Cui, Lauren Blieden, Barbara Wirostko
  Journal of Ophthalmology and Advance Research.2026; 7(3): 1.     CrossRef
• Benzothiazole-Derived Compounds as Potential Drugs for the Treatment of Type 2 Diabetes: A Descriptive Review
  Ana María Correa-Basurto, Miguel Valdes, Laura Cristina Cabrera-Pérez, Natalia Reyes Vallejo, Alejandro Cruz, Martha Cecilia Rosales-Hernández, Juan Andres Alvarado-Salazar, Jessica Elena Mendieta-Wejebe
  International Journal of Molecular Sciences.2026; 27(19): 8863.     CrossRef
• Beyond Weight Loss: Tolerability, Acceptability, and Patient-Centered Outcomes of GLP-1 Receptor Agonists in Polycystic Ovary Syndrome
  Urvah Tauseef, Farshi Farook, Vaishnavi J. Shetty, Edith Ramos-Ocola, Chandra Rupini Premkumar, Muhammad Zaryab Haider, Aashna Gandhi, Tunisha Shingala, Simardeep Singh, Muhammad Moiz Tahir, Sancia Mary Jerold Wilson, Kaaviyashri Saraboji, Jyoti Yadav, An
  Reproductive Medicine.2026; 7(4): 55.     CrossRef
• Response to comment on “Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials”
  Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam
  Sleep Medicine.2025; 134: 106709.     CrossRef
• Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
  Shikha Patel, Sarfaraz K. Niazi
  Pharmaceutics.2025; 17(8): 1036.     CrossRef
• GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective
  Pietro Carmellini, Alessandro Cuomo, Maria Beatrice Rescalli, Andrea Fagiolini
  Life.2025; 15(9): 1422.     CrossRef
• Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus
  Deyong Yue, Xuesheng Hua, Ling Zhu, Jun Wang, Lihua Gu, Zhengxia Yuan, Wenle Jian, Yirong Chen, Guoliang Meng
  Frontiers in Endocrinology.2025;[Epub]     CrossRef
• Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents
  Sherry Yun Wang, Ryan Stofer, Hao Wang, Gregory A. Brent, Lu Shi, Yu Cai, Moom Roosan, Tannaz Moin
  Diabetes & Metabolism Journal.2025; 49(6): 1331.     CrossRef
• Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders
  Ralf Weiskirchen, Amedeo Lonardo
  Medical Sciences.2025; 13(4): 265.     CrossRef
• Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management
  Ki Hoon Kwak, Chang Hee Jung
  Endocrinology and Metabolism.2025; 40(6): 879.     CrossRef
• Research Progress of GLP-1 Receptor Agonists in the Treatment of Alzheimer’s Disease
  琳娜 勾
  Advances in Clinical Medicine.2025; 15(12): 2047.     CrossRef

Citations

Citations to this article as recorded by  

• Gastroparesis needs to be detected and treated
  E. Yu. Plotnikova, A. S. Sukhikh
  Meditsinskiy sovet = Medical Council.2025; (8): 39.     CrossRef
• Real‐World Effectiveness of Rebamipide on Gastritis Symptoms: A Patient‐Focused Approach
  Hyun Ji Woo, Tae‐Kyu Kwon, Seol Ju Moon, Min‐Gul Kim
  Clinical and Translational Science.2025;[Epub]     CrossRef
• Gastric Autonomic Neuropathy in Diabetes
  Elham Hosseini-Marnani, Jessica A. Marathe, James D. Triplett, Md Kamruzzaman, Kevin Yin, Karen L. Jones, Michael Horowitz, Chinmay S. Marathe
  Endocrines.2025; 6(3): 40.     CrossRef
• INFLUENCE OF TYPE 2 DIABETES ON THE EFFICIENCY OF ENDOSCOPIC HEMOSTASIS FOR BLEEDING FROM PEPTIC GASTRODUODENAL ULCER
  V. O. Shaprynskyi, M. V. Hmoshynskyi, V. R. Taheiev
  Kharkiv Surgical School.2024; (2-3): 36.     CrossRef
• Effectiveness of Rebamipide as a part of the Helicobacter pylori eradication therapy in Russia: a meta-analysis of controlled trials
  Dmitry N. Andreev, Igor V. Maev, Dmitry S. Bordin, Svetlana V. Lyamina, Diana T. Dicheva, Aleksei K. Fomenko, Armine S. Bagdasarian
  Consilium Medicum.2022; 24(5): 333.     CrossRef
• Сompliance in patients with coronary heart disease and erosive-ulcerative gastroduodenopathy
  A. R. Molchanova, A. I. Dolgushina, A. A. Seljanina
  Experimental and Clinical Gastroenterology.2020; (6): 82.     CrossRef
• Rebamipide: evidence base for use in gastroenterology
  D. N. Andreev, I. V. Maev
  Terapevticheskii arkhiv.2020; 92(12): 97.     CrossRef
• Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis
  Mohamed Hasif Jaafar, Sher Zaman Safi, Maw-Pin Tan, Sanjay Rampal, Sanjiv Mahadeva
  Digestive Diseases and Sciences.2018; 63(5): 1250.     CrossRef
• Letter: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2016;40:240-7)
  Jin Hwa Kim
  Diabetes & Metabolism Journal.2016; 40(4): 334.     CrossRef
• Response: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7)
  Sejeong Park, So Young Park, Sang Youl Rhee
  Diabetes & Metabolism Journal.2016; 40(4): 336.     CrossRef